Search - tctmd.com

Displaying 501 - 520 of 541

Sort: Relevancy | Date

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

Michael O'Riordan

January 17, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Michael O'Riordan

December 02, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

L.A. McKeown

July 29, 2015

News Daily News

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

L.A. McKeown

July 29, 2015

News Daily News

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

L.A. McKeown

July 29, 2015

Advertisement

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

TCTMD’s Top 10 Most Popular Stories for January 2016

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

FDA approves Repatha to treat certain patients with high cholesterol

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content